Muscarinic receptor blockade with oxybutynin reduces spontaneous and induced uterine muscle contractions
Related Experiment Video
Updated: Aug 15, 2026

Contractility Measurements of Human Uterine Smooth Muscle to Aid Drug Development
Published on: January 26, 2018
Anthony G Visco1,2, Zachary R Visco3, Chad A Grotegut4
1NinoMed, LLC Chapel Hill North Carolina USA.
Objective:
The uterus and the bladder have striking physiologic and anatomic similarities. Anticholinergic medications are commonly used to treat "overactive bladder" by targeting M2 and M3 muscarinic receptors. The uterus also contains M2 and M3 muscarinic receptors; however, current management of preterm labor does not target these receptors. We assessed whether muscarinic blockade with oxybutynin reduces both spontaneous and oxytocin-induced uterine muscle contractions.
Study Design:
Longitudinal strips of uterine tissue from pregnant rats (17-19 days gestation) were mounted on an isometric test apparatus to directly measure uterine muscle contractions. The effect of cumulatively higher concentrations of oxybutynin (100 nM to 100 uM) on both spontaneous and on oxytocin-induced (1 nM) uterine muscle contractility was tested. We measured both the area under the curve (AUC) and the frequency of the uterine muscle contractions compared to water vehicle control. Measurements are presented as a percentage of baseline. Two-Way ANOVA with Dunnett's post hoc test was performed.
Results:
Uterine muscle strips harvested from pregnant rats consistently showed spontaneous muscle contractions. Oxybutynin resulted in a statistically significant decrease in both spontaneous uterine muscle strength (AUC) and contraction frequency compared to vehicle controls at concentrations ≥10 µM. Oxytocin-induced uterine muscle contractions were also affected by oxybutynin. At concentrations ≥10 µM, uterine muscle strength (AUC) was reduced (p < 0.01), but no difference was observed in contraction frequency compared to controls.
Conclusions:
Oxybutynin significantly reduces spontaneous uterine muscle contraction strength (AUC) and contraction frequency in our animal ex vivo model. It reduces oxytocin-induced uterine muscle contraction strength (AUC) but not contraction frequency. Antimuscarinic agents warrant future clinical investigation and may represent a novel treatment of preterm labor and "overactive uterus."
More Related Videos
06:22Ex Vivo Method for Assessing the Mouse Reproductive Tract Spontaneous Motility and a MATLAB-based Uterus Motion Tracking Algorithm for Data Analysis
Published on: September 1, 2019
10:26Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
Published on: August 18, 2014
Related Concept Videos
Cholinergic Antagonists: Pharmacological Actions
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Although all competitive neuromuscular blockers are designed...
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Direct-Acting Cholinergic Agonists: Pharmacological Actions
Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...